Similar results were observed in CRC, mice-bearing YTHDF1-knockdown CT26 and MC38 tumor cells showed significantly reduced tumor growth rate and weight, and the overall survival of mice receiving the combination therapy was dramatically prolonged compared with those in either monotherapy group (135). This evidence concerns the gene YTHDF1 and colorectal carcinoma.